Generic vs. Name-Brand Levothyroxine - Full Text View

Purpose

This study compares two different brands of thyroxine (thyroid hormone). Currently, pharmacists may be substituting generic formulations of thyroid hormone without your doctor knowing about this. Although a small difference in thyroid function is not significant in most healthy children, adolescents and adults, in infants and toddlers even a small difference in thyroid function can have important harmful consequences on brain development. The purpose of the present study is to learn whether the difference between brands of thyroid hormone that are currently being substituted is sufficient to cause a difference in thyroid function.

Condition	Intervention	Phase
Congenital Hypothyroidism Hypothyroidism	Drug: Levothyroxine versus Levothyroxine	Phase III

Genetics Home Reference related topics:

congenital hypothyroidism pseudoachondroplasia

ChemIDplus related topics:

Levothyroxine Sodium Thyroxine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Bio-equivalence Study

Official Title:	Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism

Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:

Thyroid Stimulating Hormone Measure [ Time Frame: 3 points over 16 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	June 2006
Estimated Study Completion Date:	March 2009
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Intervention Details:

Randomized crossover study using 8 weeks of one form of levothyroxine, then 8 weeks of the other form of levothyroxine. The dose of medication does not change throughout the duration of the study.

Detailed Description:

This study is an unblinded, randomized controlled cross-over study, which involves taking 2 different forms of levothyroxine sequentially over a 16 week period. Subjects will have a total of 3 visits over this time period. At the first visit, subjects are randomized to receive either generic (Sandoz) levothyroxine or Synthroid (Abbott) brand of levothyroxine. Blood is drawn for baseline thyroid function studies and other markers which are influenced by thyroid hormone at each visit. The second visit is the cross-over visit, and the final visit is a close-out visit, after which each subject will resume taking their previous formulation of levothyroxine.

Eligibility

Ages Eligible for Study:	3 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age between 3 and 18 years
Diagnosis of Congenital Hypothyroidism with initial TSH > 100
Ability to understand directions and follow all instructions

Exclusion Criteria:

Not on any drug interfering with absorption of levothyroxine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00403390

Contacts


Contact: Jeremi M Carswell, MD	617-355-6168	Jeremi.Carswell@childrens.harvard.edu

Locations


United States, Massachusetts
	Children's Hospital Boston	Recruiting
	Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Children's Hospital Boston

Investigators


Principal Investigator:	Rosalind S Brown, MD	Children's Hospital Boston

More Information

Responsible Party:	Children's Hospital Boston ( Rosalind Brown, MD Clinical Trials Director )
Study ID Numbers:	05-11-146
First Received:	November 21, 2006
Last Updated:	May 9, 2008
ClinicalTrials.gov Identifier:	NCT00403390
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Dwarfism

Bone Diseases, Endocrine

Cretinism

Endocrine System Diseases

Bone Diseases

Congenital hypothyroidism

Musculoskeletal Diseases

Genetic Diseases, Inborn

Congenital Hypothyroidism

Bone Diseases, Developmental

Hypothyroidism

Endocrinopathy

Thyroid Diseases

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	Children's Hospital Boston
Information provided by:	Children's Hospital Boston
ClinicalTrials.gov Identifier:	NCT00403390